Subscribe

H. Lundbeck A/S (HLUN-B.CO)

DKK41.30 -0.10 (-0.24%)
DK CPH Healthcare Drug Manufacturers - Specialty & Generic
Address Ottiliavej 9 2500
Valby, CR, DK
CEO Charl van Zyl
Website lundbeck.com
IPO 2022-06-10
ISIN DK0061804770

Explore sections of this company profile

Also trades on NASDAQ Copenhagen · HLUN-A.CO (DKK) NASDAQ Copenhagen · HLUN-B.CO (DKK) NASDAQ Copenhagen · LUN.CO (DKK) Other OTC · HLBBF (USD) Other OTC · HLUBF (USD) Other OTC · HLUYY (USD)
Description

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
DKK41.30 -0.10 (-0.24%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
693.3K
Beta
0.26
Float Shares
305.15M
Free Float %
38.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.43% -3.36% +2.94% +5.99% -9.25% -3.77% +35.49% +10.58% +27.32% +27.32% +27.32%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
41.30
DCF (Unlevered) 241.05 +483.6%
DCF (Levered) 171.09 +314.3%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 33% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 4 0
Hold 7 0
Sell 0 0
Strong Sell 1 0
Quality scores
Altman Z-Score
2.34
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A+
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +10.7% ★ Q1'26: +12.7% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +1.6% Q1'26: +44.0% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +16.8% Q1'26: +6.9% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +20.7% ★ Q1'26: +33.6% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +10.7% ★ Q1'26: +30.5% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.1% Q1'26: +0.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    1.64× Q1'26: 0.05× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.58) × ERP
WACC = 77% × Ke + 23% × Kd (4.5%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 241.05 Current price: 41.30
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
11 Rev. Ana.
9 EPS Ana. 		Dec 2027
11 Rev. Ana.
9 EPS Ana. 		Dec 2028
9 Rev. Ana.
7 EPS Ana. 		Dec 2029
4 Rev. Ana.
2 EPS Ana. 		Dec 2030
4 Rev. Ana.
5 EPS Ana.
Revenue
14.59B
est: 14.28B (+2.2%)
15.63B
est: 15.57B (+0.4%)
17.23B
est: 17.24B (0.0%)
17.88B
est: 18.08B (-1.1%)
17.36B
est: 16.86B (+3.0%)
17.67B
est: 17.76B (-0.5%)
16.30B
est: 16.36B (-0.4%)
18.25B
est: 18.11B (+0.7%)
19.91B
est: 20.67B (-3.7%)
22.00B
est: 22.13B (-0.6%)
24.35B
est: 24.53B (-0.7%)
25.50B
25.24B – 25.69B
+4.0% YoY
25.53B
24.25B – 26.42B
+0.1% YoY
24.80B
24.75B – 24.86B
-2.9% YoY
22.91B
22.22B – 23.40B
-7.6% YoY
21.80B
21.14B – 22.26B
-4.9% YoY
EBITDA
498.00M
est: 3.55B (-86.0%)
3.58B
est: 3.87B (-7.4%)
5.62B
est: 4.28B (+31.4%)
5.29B
est: 4.49B (+17.8%)
4.78B
est: 4.19B (+14.2%)
4.88B
est: 4.41B (+10.7%)
3.44B
est: 4.06B (-15.2%)
4.39B
est: 4.50B (-2.4%)
5.06B
est: 8.05B (-37.1%)
5.71B
est: 8.61B (-33.7%)
7.34B
est: 9.55B (-23.1%)
9.93B
9.82B – 10.00B
+4.0% YoY
9.94B
9.44B – 10.29B
+0.1% YoY
9.65B
9.63B – 9.68B
-2.9% YoY
8.92B
8.65B – 9.11B
-7.6% YoY
8.48B
8.23B – 8.66B
-4.9% YoY
EBIT
-6.53B
est: 1.98B (-429.9%)
2.24B
est: 2.16B (+3.6%)
4.37B
est: 2.39B (+83.1%)
5.29B
est: 2.51B (+111.1%)
3.09B
est: 2.34B (+32.2%)
2.09B
est: 2.46B (-15.2%)
1.73B
est: 2.27B (-23.5%)
2.58B
est: 2.51B (+2.7%)
3.05B
est: 6.39B (-52.3%)
3.83B
est: 6.84B (-44.0%)
5.03B
est: 7.58B (-33.7%)
7.88B
7.80B – 7.94B
+4.0% YoY
7.89B
7.49B – 8.17B
+0.1% YoY
7.66B
7.65B – 7.68B
-2.9% YoY
7.08B
6.87B – 7.23B
-7.6% YoY
6.74B
6.53B – 6.88B
-4.9% YoY
Net Income
-5.69B
est: 136.86M (-4,260.5%)
1.21B
est: 1.96B (-38.1%)
2.62B
est: 3.02B (-13.1%)
3.91B
est: 3.84B (+1.8%)
2.67B
est: 2.50B (+6.8%)
1.58B
est: 1.22B (+29.9%)
1.32B
est: 1.29B (+2.2%)
1.92B
est: 1.69B (+13.1%)
2.29B
est: 2.59B (-11.4%)
3.14B
est: 2.92B (+7.7%)
3.19B
est: 4.00B (-20.2%)
4.45B
4.37B – 4.74B
+11.3% YoY
4.73B
4.21B – 5.00B
+6.2% YoY
4.28B
3.33B – 5.05B
-9.4% YoY
4.06B
3.90B – 4.17B
-5.3% YoY
3.45B
3.32B – 3.55B
-14.8% YoY
SGA
7.87B
est: 6.02B (+30.7%)
6.29B
est: 6.56B (-4.1%)
6.48B
est: 7.27B (-10.8%)
6.04B
est: 7.62B (-20.7%)
6.41B
est: 7.11B (-9.7%)
6.91B
est: 7.48B (-7.7%)
6.82B
est: 6.89B (-1.1%)
7.69B
est: 7.63B (+0.7%)
8.78B
est: 8.59B (+2.2%)
9.58B
est: 9.19B (+4.3%)
8.78B
est: 10.19B (-13.8%)
10.59B
10.48B – 10.67B
+4.0% YoY
10.60B
10.07B – 10.97B
+0.1% YoY
10.30B
10.28B – 10.33B
-2.9% YoY
9.52B
9.23B – 9.72B
-7.6% YoY
9.05B
8.78B – 9.25B
-4.9% YoY
EPS
-28.98
est: 0.14 (-21,093.9%)
6.14
est: 1.97 (+211.3%)
13.28
est: 3.05 (+335.8%)
19.67
est: 3.87 (+408.1%)
13.42
est: 2.52 (+432.9%)
7.96
est: 1.23 (+548.4%)
1.66
est: 1.30 (+27.7%)
1.93
est: 1.71 (+13.0%)
2.31
est: 2.61 (-11.4%)
3.17
est: 2.96 (+7.2%)
3.22
est: 4.02 (-20.0%)
4.58
4.40 – 4.78
+13.8% YoY
4.64
4.24 – 5.04
+1.2% YoY
4.31
3.35 – 5.09
-7.1% YoY
4.09
3.93 – 4.20
-5.1% YoY
3.48
3.34 – 3.58
-14.8% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-13 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-12 A- 4/5 5/5 4/5 4/5 2/5 3/5 3/5
2026-05-11 A- 4/5 5/5 4/5 4/5 2/5 3/5 3/5
2026-05-08 A 4/5 5/5 4/5 4/5 2/5 3/5 4/5
2026-05-07 A 4/5 5/5 4/5 4/5 2/5 3/5 4/5
2026-05-06 A 4/5 5/5 4/5 4/5 2/5 3/5 4/5
2026-05-05 A 4/5 5/5 4/5 4/5 2/5 3/5 4/5
2026-05-04 A 4/5 5/5 4/5 4/5 2/5 3/5 4/5
2026-04-30 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-04-29 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-28 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-27 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-24 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-23 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-22 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-21 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-20 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-17 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-16 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
4.63B
OE per share TTM
4.66
Owner's Yield
11.27%
Maintenance CapEx ratio
0.11%
Maint CapEx / Avg PPE
14.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 93 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares MSCI Denmark ETF EDEN 0.88% 1.81M 0.53%
2 Vident International Equity Strategy ETF VIDI 0.38% 1.51M 0.61%
3 iShares Healthcare Innovation UCITS ETF HEAL.L 0.20% 2.31M 0.40%
4 Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE 0.20% 689.3K 0.23%
5 Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA 0.20% 689.3K 0.23%
6 Goldman Sachs Data Enhanced International Equity ETF GIEQ 0.18% 18.5K 0.30%
7 Dimensional - International Small Cap Value ETF DISV 0.15% 7.30M 0.42%
8 iShares Ageing Population UCITS ETF AGED.L 0.15% 1.32M 0.40%
9 State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE 0.12% 925.2K 0.30%
10 iShares MSCI Europe Small-Cap ETF IEUS 0.12% 206.9K 0.41%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
946.0K
Shares Outstanding
793.13M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Charl van Zyl President & Chief Executive Officer 20M male
Per Johan Luthman Executive Vice President of Research & Development 9M —
Joerg Hornstein Chief Financial Officer & Executive Vice President of Corporate Functions 9M male
Lars Bang Executive Vice President of Product Development & Supply 8M male
Johannes Rolf Streffer Senior Vice President & Head of Global Clinical Development — —
Jens Hoyer Vice President & Head of Investor Relations — —
Dianne Holto Executive Vice President of People, Culture & Sustainability — female
Tarek Samad Senior Vice President & Head of Research — —
Thomas E. Gibbs Executive Vice President & Head of Lundbeck in United States — male
Tine Ostergaard Hansen Senior Vice President of Corporate Communications & Public Affairs — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic